This manuscript reports the results of an evaluation of two community-based booster seat promotion programs in Michigan; one program focused on a low-income community, while the other focused on a Hispanic community. Each community received funding to develop and implement a booster seat intervention program specific to their community. To determine the effectiveness of each program, direct obs...

OBJECTIVES Booster vaccination against 2009 H1N1 influenza virus was recommended for rheumatologic patients under immunosuppressive therapy during the 2009/2010 H1N1 pandemic. In this study we assessed whether B cell depletion with rituximab influences of the antiviral immune response in 2009 H1N1 influenza virus-vaccinated patients. METHODS Influenza virus-specific immune responses were anal...

BACKGROUND AND AIMS The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV) vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old children. METHODS This clinical trial st...

Background: Patients with rheumatologic immune-mediated diseases (R-IMID) Latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at an increased risk of active (TB). Screening LTBI tuberculin skin test (TST) and/or Interferon (IFN)-γ release assays (IGRA) is recommended before starting BT. Objectives: In patients R-IMID previously to BT our aim was assess a ) prevalence LTBI, ...

An ultra-low voltage customized DC-DC booster circuit was developed using a LTC3108 converter, and used continuously on a flat-plate microbial fuel cell (FPM) system. The boost converter successfully stepped up the microbial fuel cell (MFC) voltage from ~0.5 V to 3.3 and 5.0 V of outputs. The designed circuit and system displayed the dynamic variations of the source FPM as well as the output vo...

Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 μg A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.

Introduction Pertussis is re-emerging worldwide, despite effective immunization programs for infants and children. Epidemiological studies show a more limited duration of protection against clinical pertussis in adolescents primed with acellular pertussis (aP) vaccines during infancy than those who have been primed with whole-cell pertussis (wP) vaccines. This study aimed to determine whether m...

This study was designed to assess atrial booster pump action in valvular heart disease and to dissect booster pump from reservoir-conduit functions. In five patients with aortic stenosis and six with mitral stenosis, sequential atrioventricular (A-V) pacing was instituted during the course of diagnostic cardiac catheterization. Continuous recording of valvular gradient allowed estimation of flo...

The changes in lgG antibody levels to hepatitis B surface antigen (HBsAg) and in antibody to HBsAg (anti-HBs) seroconversion rates due to different dosages of hepatitis B vaccine (HepB) were compared in 2106 children. Children who had been previously vaccinated as infants with HepB were revaccinated at 5-15 y of age, after which the antibody titers were determined. After the first booster dose,...

This phase II study evaluated the effect of chloroquine on the specific CD8(+) T-cell responses to and the safety of a booster dose of investigational human immunodeficiency virus type 1 (HIV-1) F4/AS01(B) vaccine containing 10 μg of recombinant fusion protein (F4) adjuvanted with the AS01(B) adjuvant system. Healthy adults aged 21 to 41 years, primed 3 years before with two F4/AS01(B) doses co...